Avexitide for hypoglycemia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 24 Dec 2024: Trial registered, NCT06747468
  2. 29 Apr 2025: Trial started, NCT06747468

The trials

NCT01803451: Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

State
Under way
Phase
Early Phase 1
People
80 planned
Started
Nov 2005
Primary completion
Aug 2026
Arms
hyperglycemic clamp-Meal tolerance test, Labeled meal tolerance test
Results
None posted
  1. 4 Mar 2013: Trial registered

NCT06747468: Avexitide for Treatment of Post-Bariatric Hypoglycemia

State
Under way
Phase
Phase 3
People
75 planned
Started
29 Apr 2025
Primary completion
8 Jul 2026
Arms
AVEXITIDE
Results
None posted
  1. 24 Dec 2024: Trial registered
  2. 29 Apr 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Liq avexitide, Lyo avexitide, exendin -(9-39), exendin 9-39, exendin-(9-39).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.